Protein Expression in Down Syndrome Brain
Editat de G. Lubecen Limba Engleză Hardback – 15 oct 2001
Preț: 1211.43 lei
Preț vechi: 1477.35 lei
-18% Nou
Puncte Express: 1817
Preț estimativ în valută:
231.82€ • 243.82$ • 193.70£
231.82€ • 243.82$ • 193.70£
Carte tipărită la comandă
Livrare economică 08-22 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783211837320
ISBN-10: 3211837329
Pagini: 388
Ilustrații: X, 374 p.
Dimensiuni: 210 x 279 x 30 mm
Greutate: 1.29 kg
Ediția:2001
Editura: SPRINGER VIENNA
Colecția Springer
Locul publicării:Vienna, Austria
ISBN-10: 3211837329
Pagini: 388
Ilustrații: X, 374 p.
Dimensiuni: 210 x 279 x 30 mm
Greutate: 1.29 kg
Ediția:2001
Editura: SPRINGER VIENNA
Colecția Springer
Locul publicării:Vienna, Austria
Public țintă
ResearchCuprins
Decreased alpha-endosulfine, an endogenous regulator of ATP-sensitive potassium channels, in brains from adult Down syndrome patients.- Developmental instability of the cerebellum and its relevance to Down syndrome.- Expression of the multidrug resistance P glycoprotein (Pgp) and multidrug resistance associated protein (MRP1) in Down syndrome brains.- Deterioration of the transcriptional, splicing and elongation machinery in brain of fetal Down Syndrome.- Fetal life in Down Syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure.- Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome.- Glial-neurotrophic mechanisms in Down syndrome.- Aberrant expression of dihy-dropyrimidinase related proteins-2, -3 and -4 in fetal Down Syndrome brain.- Decreased protein levels of complex I 30-kDa subunit in fetal Down Syndrome brains.- Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome.- Functional genomics of Down Syndrome: a multidisciplinary approach.- Unaltered expression of Fas (CD95/APO-1), Caspase-3, Bcl-2 and Annexins in brain of fetal Down syndrome: evidence against increased apoptosis.- Alteration of caspases and other apoptosis regulatory proteins in Down syndrome.- Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF-kB in brains of patients with Down syndrome.- Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down Syndrome and Alzheimer’s disease.- Carbohydrate handling enzymes in fetal Down Syndrome brain.- Changes in nicotinic acetylcholine receptor subunits expression in brain of patients withDown syndrome and Alzheimer’s disease.- Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer’s disease and Down Syndrome.- Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome.- The brain in Down syndrome.- Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer’s disease.- Increased protein levels of heterogeneous nuclear ribonucleoprotein A2/B1 in fetal Down syndrome brains.- Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimer’s disease.- Molecular neuropathology of transgenic mouse models of Down syndrome.- Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation.- Expression profiles of proteins in fetal brain with Down syndrome.- Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down Syndrome: dysregulation of T-complex protein 1.- ß-Amyliod precursor protein, ETS-2 and collagen alpha 1 (VI) chain precursor, encoded on chromosome 21, are not overexpressed in fetal Down syndrome: further evidence against gene dosage effect.- Reduction of nucleoside diphosphate kinase B, Rab GDP-dissociation inhibitor beta and histidine triad nucleotide-binding protein in fetal Down Syndrome brain.- Alteration of gene expression in Down’s syndrome (DS) brains: its significance in neurodegeneration.